Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | THPO | P40225 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708578 | 0.91 | SIGMAR1 (0.73) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL467279 | 0.90 | SIGMAR1 (0.71) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7288768 | 0.86 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL1298887 | 0.85 | SIGMAR1 (0.73) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7280212 | 0.85 | SIGMAR1 (0.59) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1299467 | 0.84 | SIGMAR1 (0.71) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9646859 | 0.84 | SIGMAR1 (0.58) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL19557301 | 0.83 | LTA4H (0.75) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL7031231 | 0.83 | SIGMAR1 (0.68) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL26981197 | 0.83 | LTA4H (0.75) | SLC6A4SLC6A3SLC6A2SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600873-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | ChanRx Corporation (US) | 2013-06-12 | — | — | EP | claimed |
| WO-2012018795-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | CHANTEST CORPORATION (US) | 2012-02-09 | — | — | WO | claimed |
| US-20120028992-A1 | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals | LAGUNA PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | claimed |
| EP-2600873-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | ChanRx Corporation (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2600873-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | ChanRx Corporation (US) | 2013-06-12 | — | — | EP | disclosed |
| CN-103153310-A | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals | CHANTEST CORP | 2013-06-12 | — | — | CN | disclosed |
| WO-2012018795-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | CHANTEST CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012018795-A1 | PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND/OR MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS | CHANTEST CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028992-A1 | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals | LAGUNA PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| US-20120028992-A1 | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals | LAGUNA PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028992-A1 | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals | RYR2, KCNH1, SCN5A | SLC6A4 4034/4885SLC6A3 4023/4885SLC6A2 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.